Abeona Therapeutics Inc.
ABO-701
advanced prostate cancer
Countdown
542days
Catalyst readout · ~ Dec 31, 2027 estimated
What's at stake
A key catalyst for ABO-701 (advanced prostate cancer) is expected ~ Dec 31, 2027.
Primary source
· SEC 8-K
verified 15h ago
“Abeona expects to file an Investigational New Drug (IND) application and commence first-in-human studies with ABO-701 in the second half of 2027”